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a  b  s  t  r  a  c  t
Sepsis  is  a systemic  inﬂammatory  response  syndrome  during  infection.  Therapeutic  agents
are essential  to protect  the host from  sepsis.  Ovocalyxin-36  (OCX-36)  is  a chicken  eggshell
membrane  protein  and  shares  protein  sequence  and gene  organization  homology  with  bac-
tericidal permeability-increasing  protein  (BPI),  lipopolysaccharide-binding  protein  (LBP)
and  palate,  lung  and nasal  epithelium  clone  (PLUNC)  proteins  that play  a major  role  in
innate  immune  protection.  We  recently  reported  that  OCX-36  binds  to  both  lipopolysaccha-
ride  (LPS)  and  lipoteichoic  acid  (LTA)  (Cordeiro  et al.,  2013,  PLoS  ONE  8, e84112),  which  is  an
important  activity  to  neutralize  endotoxins  and  non-endotoxin  pyrogens  during  an  inﬂam-
matory response.  Here  we investigated  the  immune  modulating  effects  of OCX-36  and
enzymatically  digested  OCX-36  (dOCX-36)  in  vitro  and  in  a mouse  model  of endotoxemia.
OCX-36  alone  dose-dependently  induced  both  TNF-  and  nitric  oxide  (NO)  production  by
RAW  264.7  macrophage  cells,  and  this  immunostimulatory  effect  was  reduced  by enzymatic
digestion.  In the  presence  of LPS, dOCX-36  was  more  effective  than intact  OCX-36  at  reduc-
ing  LPS-induced  secretion  of TNF-  from  RAW  264.7  cells,  but  did  not  reduce  NO production.
In  contrast,  OCX-36  increased  LPS-induced  NO production,  both  in  the  presence  and absence
of FBS,  PCR  array  analysis  conﬁrmed  that  OCX-36  and  dOCX-36  differentially  regulated
genes  involved  in  innate  immunity,  and  dOCX-36  down-regulated  the  expression  of  genes
involved  in LPS  signaling  and  inﬂammatory  responses.  In  vivo,  dOCX-36  was  more  effective
at reducing  LPS-induced  inﬂammatory  symptoms  and  inhibiting  the local  production  of
pro-inﬂammatory  mediators  in  the  small  intestine.  These  results  suggest  that  OCX-36  and
OCX-36  derived  peptides  may  differentially  modulate  innate  immune  responses,  and  sup-
port  our  hypothesis  that  OCX-36  derived  peptides  have  potential  therapeutic  applications
in sepsis.
©  2014  The  Authors.  Pub
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1. Introduction
Sepsis is a disease characterized by the invasion of
bacterial pathogens into the bloodstream that activates
an inﬂammatory response. The uncontrolled immune
response leads to septic shock that involves tissue damage
and multiple organ dysfunction and failure (Opal, 2007).
LPS is the main component of the Gram-negative bac-
terial cell wall and the principal activator of the innate
immune system which promotes the production of pro-
inﬂammatory mediators during infection (Beutler and
Rietschel, 2013). LPS is one of several pathogen-associated
molecular patterns (PAMPs) and is recognized by Toll-
like receptor (TLR) 4 which is expressed on the surface
of macrophages. This stimulates the host cells to secrete a
large amount of proinﬂammatory mediators and cytokines
such as nitric oxide (NO), tumor necrosis factor (TNF)-,
and interleukins (ILs) (Kumar et al., 2009). NO and TNF-
are associated with antimicrobial activity, the host innate
immune response to pathogens and tumor cell killing
(Bogdan, 2001).
The toxic effect of LPS is modulated by a large fam-
ily of proteins such as the LBP/BPI/PLUNC protein family.
These proteins bind LPS and mediate the LPS signal
to innate immune receptors (Wiesner and Vilcinskas,
2010). For example, BPI protein suppresses the delivery
of LPS to immune receptors and promotes LPS uptake
by macrophages via the macrophage phagocytic process
(Iovine et al., 2002). On the other hand, low concen-
trations of LBP deliver LPS to CD14 molecules and then
boost the inﬂammatory response induced by LPS; in con-
trast, high concentrations of LBP reduce LPS activation of
macrophages (Lamping et al., 1998). Some studies have
reported that LBP/BPI/PLUNC proteins inhibit proinﬂam-
matory activities of LPS in macrophages such as induction
of cytokines secretion, stimulation of neutrophil oxidase
enzymes and NO formation (Schumann, 2001; Lukinskiene
et al., 2011).
The current therapy for severe sepsis and septic shock
includes treatment of circulatory failure, the administra-
tion of antibiotics and the use of activated protein C (Rivers
et al., 2001). Newer strategies are the identiﬁcation and
development of improved antimicrobial peptides that also
neutralize the LPS functionality that leads to overpro-
duction of proinﬂammatory mediators (Schuerholz et al.,
2012).
OCX-36 is an avian protein enriched in the eggshell
membranes of chicken eggs. OCX-36 shares similarity in
protein sequence and gene structure with LBP, BPI and
PLUNC proteins, which is the origin of our hypothesis
that OCX-36 participates in the innate immune protection
against pathogens (Gautron et al., 2007). We  have recently
characterized the biological function of puriﬁed OCX-36
extracted from eggshell membranes, demonstrating that it
is a pattern recognition molecule (PRR) which has antimi-
crobial activity against S. aureus and the ability to bind to
Escherichia coli LPS and to S. aureus LTA (Cordeiro et al.,
2013).
In order to evaluate the potential of OCX-36 for ther-
apeutic and neutraceutical applications, we compared
whole and enzymatically digested OCX-36 to determinend Immunopathology 160 (2014) 1–11
their immune-stimulating and anti-endotoxin properties
in vivo and in vitro.
2. Materials and methods
2.1. Materials
Dulbecco’s modiﬁed Eagle’s medium (DMEM), sodium
pyruvate and penicillin–streptomycin were purchased
from Gibco. FBS was  purchased from Cansera. 48-
Well tissue culture plates and 96-well medium binding
microplates were purchased from Corning Costar. Recom-
binant mouse TNF-, IL-6, and IL-1, anti-mouse TNF-,
IL-6, and IL-1 antibodies, biotinylated anti-mouse TNF-
, IL-6, and IL-1 antibodies, and avidin-conjugated HRP
were purchased from BD Biosciences. Mouse TNF- and
IL-6 ELISA Ready-SET-Go® kits were purchased from
eBioscience. WST-1 Cell Proliferation Reagent was pur-
chased from Roche Applied Science. Bicinchoninic acid
(BCA) protein assay, bovine serum albumin (BSA), cell
culture grade water (endotoxin-free, <0.005 EU/mL) and
Limulus Amebocyte Lysate (LAL) Chromogenic Endotoxin
Quantiﬁcation Kit were purchased from Thermo Sci-
entiﬁc. Pepsin from porcine gastric mucosa, LPS from
E. coli O111:B4, PMSF, aprotinin, leupeptin, pepstatin
A, 3,3′,5,5′′-tetramethylbenzidine (TMB) and hexade-
cyltrimethyl ammonium bromide (HTAB) were purchased
from Sigma–Aldrich. The Griess reagent system was pur-
chased from Promega. AurumTM Total RNA Mini Kit was
purchased from Bio-Rad Laboratories. RT2 First Strand
cDNA Kit and Mouse Innate and Adaptive Immune
Response RT2 Proﬁler PCR Array were purchased from SA
Biosciences.
2.2. Ovocalyxin-36
OCX-36 was extracted from eggshell membranes and
puriﬁed as previously described (Cordeiro et al., 2013).
Puriﬁed OCX-36 was  dissolved in PBS buffer (10 mM
sodium phosphate buffer, 0.154 M NaCl, pH 7.4) prepared
with endotoxin-free water (<0.005 EU/mL) and the concen-
trations of OCX-36 for all assays were determined by the
BCA protein assay using BSA as standard. Endotoxin lev-
els in OCX-36 samples were measured by the LAL assay
(Thermo Scientiﬁc).
2.3. Enzymatic digestion of OCX-36
To prepare pepsin-digested OCX-36, freeze-dried OCX-
36 (2 mg/mL) was dissolved in 0.15 M HCl, and pepsin was
added to the OCX-36 solution at an enzyme to substrate
ratio of 1:250 (w/w). Samples were incubated at 37 ◦C for
0, 30 s; 1.5, 5 and 30 min; and 1.5 h, 5 h and 10 h, followed
by heating at 90 ◦C for 5 min  to inactivate the enzyme.
The digested samples were dialyzed against water (MWCO
100 Da; Spectrum Laboratories, Inc.) and lyophilized for
further use in cell culture and animal studies.To prepare thermolysin-digested OCX-36, freeze dried
OCX-36 was dissolved in endotoxin-free PBS buffer and
diluted in thermolysin digestion buffer (50 mM Tris–HCl,
0.5 mM CaCl2, pH 7.4). Thermolysin was  dissolved in the
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ame buffer and was added at an enzyme to substrate ratio
f 1:100 (w/w). Samples were incubated at 65 ◦C for 15 min,
0 min; and 1 h, 1.5 h and 4 h. After digestion, the enzyme
as inactivated by heating at 95 ◦C for 15 min  and then
ooled for 10 min  at room temperature. Samples were cen-
rifuged at 13,000 rpm (Biofuge Pico Heraeus Instruments)
t 4 ◦C for 10 min.
.4. Electrophoresis for OCX-36 analysis
SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
as performed as previously described (Hincke and Nairn,
992), followed by staining with Coomassie Blue and
estaining.
.5. Cell culture
RAW 264.7 cells (ATCC) were cultured in DMEM
upplemented with 1 mM sodium pyruvate, 50 U/mL of
enicillin–streptomycin and 10% FBS, and were grown at
7 ◦C in a 5% CO2 chamber. Cell passages 2–10 were used.
ells were seeded into 48-well tissue culture plates at
 density of 5 × 105 cells/well and allowed to adhere for
6–18 h before treatment. OCX-36 or dOCX-36 (with or
ithout LPS) was either diluted into the culture medium
500 L) from concentrated stocks (10 L) (for measure-
ents of NO secretion) or prediluted in medium and added
o the wells (500 L) after aspiration of the culture medium
TNF- secretion), in order to obtain the ﬁnal, stated, con-
entrations.
.6. Evaluation of anti-endotoxin activity in vitro
RAW 264.7 cells were treated with OCX-36 or
nzymatically-digested OCX-36 (dOCX-36), in the presence
r absence of E. coli O111:B4 LPS, in DMEM contain-
ng 10% FBS. To examine the effect on NO production,
ells were incubated for 24 h in the presence of medium
lone, 10 ng/mL LPS, OCX-36 or dOCX-36 alone, or LPS
re-incubated for 1 h with OCX-36 or dOCX-36 at the
ndicated concentrations. For TNF- secretion and gene
xpression analysis by PCR array, cells were incubated for
 h in the presence of medium alone, 100 ng/mL LPS, OCX-
6 or dOCX-36 alone, or LPS pre-incubated with OCX-36 or
OCX-36 at the indicated concentrations.
To evaluate the potential role of LBP on the anti-
ndotoxin activity of OCX-36, cells were washed twice with
BS and treated as described above with OCX-36 in the
resence or absence of LPS in serum-free DMEM.  After incu-
ation for 6 or 24 h, culture supernatants were collected for
easurement of TNF- and NO, respectively.
.7. Evaluation of anti-endotoxin activity in vivo
Balb/c mice (18–20 g, 6–8 mice/group; Charles River
aboratories, Inc.) were injected intraperitoneally (i.p.)
ith 2 or 10 mg/kg body weight (BW) OCX-36 or dOCX-36
ombined with 25 g E. coli O111:B4 LPS in sterile saline, in
 total volume of 100 L. Positive control mice received LPS
lone, and negative control mice received saline only. Twond Immunopathology 160 (2014) 1–11 3
control groups were given 10 mg/kg BW OCX-36 or dOCX-
36 alone in sterile saline. Mice were monitored for clinical
symptoms and weighed 24 h after LPS administration.
To further examine the acute local and systemic effects,
mice were injected i.p. with 10 mg/kg BW OCX-36 or dOCX-
36 combined with 25 g E. coli O111:B4 LPS in sterile saline.
Positive control mice received LPS alone, and negative con-
trol mice received saline. After 2 h, mice were humanely
euthanized and blood, liver, and small intestine (ileum)
samples were collected. Blood was  processed for serum and
stored at −20 ◦C, and liver and ileum samples were ﬂash
frozen and stored at −80 ◦C until further analysis.
All animal procedures were carried out in accordance
with the Canadian Council of Animal Care Guide to the
Care and Use of Experimental Animals and were approved
by the University of Guelph Animal Care Committee (AUP
#07R116).
2.8. Cell viability assay
Cell viability was  measured using the WST-1 Cell Pro-
liferation Reagent (Roche) according to the manufacturer’s
instructions.
2.9. Nitric oxide (NO) assay
The NO concentration in culture supernatants was
determined using the Griess Reagent System (Promega)
according to the manufacturer’s protocol.
2.10. Cytokine ELISAs
Measurement of TNF- concentration in culture super-
natants was carried out by ELISA according to the
manufacturer’s instructions (BD Biosciences), and results
are expressed as percent TNF- secretion relative to posi-
tive control (LPS) cells.
To measure TNF-, IL-6 and IL-1 concentrations in
liver and ileum samples, tissues were homogenized in 1 mL
ice-cold PBS containing 0.5% Triton X-100, 1 mM PMSF,
10 g/mL aprotinin, 10 g/mL leupeptin, and 10 g/mL
pepstatin A using a Polytron® homogenizer (PT 1200;
Kinematica, Inc., Switzerland). Homogenates were clari-
ﬁed by centrifugation at 12,000 rpm for 15 min  at 4 ◦C
(Biofuge Fresco, Heraeus Instruments). TNF-, IL-6 and
IL-1 concentrations were measured by ELISA accord-
ing to the manufacturer’s instructions (BD Biosciences).
TNF- and IL-6 concentrations in serum were determined
using mouse TNF- and IL-6 ELISA Ready-SET-Go® kits
(eBioscience) according to the manufacturer’s instructions.
Cytokine concentrations are expressed as pg or ng cytokine
per mL  serum, or ng cytokine per g tissue.
2.11. Myeloperoxidase (MPO) activity
Homogenate pellets from liver and ileum samples
(Section 2.10) were re-homogenized in 1 mL  of 50 mM
potassium phosphate, pH 6.0 containing 0.5% (w/v) HTAB,
and subjected to two  freeze–thaw cycles. Samples were
clariﬁed by centrifugation at 12,000 rpm for 10 min  at
nology and Immunopathology 160 (2014) 1–11
Fig. 1. Effect of OCX-36 on TNF- and NO secretion in LPS-stimulated
RAW 264.7 cells. (A) Cells were treated with 0, 0.1, 1, 10 or 100 g/mL
OCX-36 in the presence or absence of 100 ng/mL E. coli LPS for 6 h. TNF-
concentration was measured by ELISA, and is presented as percent TNF-
  relative to positive control cells treated with LPS alone. (B) Cells were
treated with 0, 1, 10 or 100 g/mL OCX-36 in the presence or absence of
10  ng/mL E. coli LPS for 24 h. NO concentration was measured using Griess
reagent and is presented as percent NO relative to positive control cells.
Data represent means ± SEM, n = 3. Values without a common letter are
signiﬁcantly different at p < 0.05.4 J. Kovacs-Nolan et al. / Veterinary Immu
4 ◦C (Biofuge Fresco, Heraeus Instruments), and super-
natants were assayed for MPO  activity. Brieﬂy, samples
were diluted in HTAB buffer and mixed with a 1.6 mM TMB
solution in 0.3 mM H2O2. One unit (U) of enzyme activity
was deﬁned as the amount of MPO  present that caused a
change in absorbance of 1.0/min at 655 nm.  MPO  activities
are expressed as mU  MPO  per g tissue.
2.12. RNA isolation and PCR array analysis
Total RNA was extracted from RAW 264.7 cells using
the AurumTM Total RNA Mini Kit (Bio-Rad Laborato-
ries) according to the manufacturer’s instructions. One
microgram of RNA was reverse transcribed using the
RT2 First Strand cDNA Kit (SA Biosciences), and the
expression of 84 genes involved in the host response
to bacterial infection and sepsis were analyzed simul-
taneously using a Mouse Innate and Adaptive Immune
Response RT2 Proﬁler PCR Array (SA Biosciences) accord-
ing to the manufacturer’s instructions. PCR was carried
out using a MyiQ Single Color Real-Time PCR Detection
System (Bio-Rad) and data were analyzed using the
instructions and template provided by the manufac-
turer (http://www.sabiosciences.com/dataanalysis.php).
Results are expressed as -fold change relative to untreated
cells. A gene was considered to be differentially expressed
when it had a fold change of at least ±2.0.
2.13. Statistical analysis
All analyses were performed in triplicate unless speci-
ﬁed otherwise. Statistical analyses were carried out using
GraphPad Prism version 5.0 (GraphPad). Statistical signif-
icance was determined by Student’s t-test with p < 0.05
taken as signiﬁcant. Results are reported as mean ± SEM.
3. Results
3.1. Anti-endotoxin effects in vitro
3.1.1. The effect of OCX-36 on LPS-induced secretion of
TNF-  ˛ and NO in murine macrophages
To investigate the effect of OCX-36 on TNF- and NO
production in murine macrophages, RAW 264.7 cells were
incubated with varying concentrations of OCX-36 and in
the presence or absence of E. coli LPS. Treatment with LPS
signiﬁcantly increased TNF- production in RAW 264.7
when compared to untreated control cells (p < 0.05), and
this was decreased (p < 0.05) by OCX-36 at concentra-
tions of 0.1, 1 and 10 g/mL (Fig. 1A). In contrast, OCX-36
had no pronounced effect on LPS-induced NO production
(Fig. 1B).
Surprisingly, treatment of RAW 264.7 cells with OCX-36
alone, without LPS stimulation, signiﬁcantly increased both
TNF- and NO production (p < 0.05) compared to untreated
control cells, when added at concentrations greater than
1 g/mL (Fig. 1A and B). This was not associated with
endotoxin contamination in OCX-36 samples, since the
endotoxin levels measured in OCX-36 samples using the
LAL assay were lower than 1 ng/mL (0.11 ± 0.04 EU/g of
OCX-36, 0.02 ± 0.01 ng/g of OCX-36), and this level ofendotoxin (LPS) was found not to induce NO production
in RAW 264.7 cells.
To further examine the effect of LBP, which is nat-
urally present in FBS, on the anti-endotoxin activity of
OCX-36, RAW 264.7 cells were treated with OCX-36 and
LPS in serum-free medium. Similar to the results obtained
in medium containing FBS, OCX-36 at concentrations of
0.1, 1 and 10 g/mL signiﬁcantly reduced TNF- secre-
tion (p < 0.05) (Fig. 2A). However, in the absence of serum,
OCX-36 treatment at 1 and 10 g/mL resulted in a >25%
decrease in LPS-induced TNF- secretion, compared to only
a 12% reduction in the presence of FBS, at the same OCX-
36 concentrations. OCX-36 did not reduce NO production
in LPS-activated RAW 264.7 cells in the absence of serum,
but rather OCX-36 at 100 g/mL signiﬁcantly increased
LPS-induced NO secretion when compared to cells treated
with LPS alone (p < 0.5) (Fig. 2B). No effect of OCX-36 or
LPS treatment was  observed on cell viability (data not
shown).
J. Kovacs-Nolan et al. / Veterinary Immunology and Immunopathology 160 (2014) 1–11 5
Fig. 2. Effect of OCX-36 on TNF- and NO production in LPS-stimulated
RAW 264.7 cells in the absence of FBS. (A) Cells were treated with 0, 0.1,
1,  10 or 100 g/mL OCX-36 in the presence of 100 ng/mL E. coli LPS for
6  h in serum-free medium. TNF- concentration was measured by ELISA,
and is presented as percent TNF- relative to positive control cells treated
with LPS alone. (B) Cells were treated with 0, 0.1, 10 or 100 g/mL OCX-
36  in the presence of 10 ng/mL E. coli LPS for 24 h in serum-free medium,
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Fig. 3. SDS-PAGE analysis of OCX-36 digested with pepsin and ther-nd NO concentration was  measured using Griess reagent. Data repre-
ent means ± SEM, n = 3. Values without a common letter are signiﬁcantly
ifferent at p < 0.05.
.1.2. The effect of dOCX-36 on TNF-  ˛ and NO production
n LPS-activated murine macrophages
The effect of OCX-36-derived peptides (dOCX-36) on
NF- and NO release by RAW 264.7 macrophages stim-
lated with E. coli LPS was also examined. OCX-36 was
igested with pepsin for up to 10 h, and digestion was mon-
tored at intervals by SDS-PAGE. OCX-36 appeared to be
ompletely digested by pepsin after 1.5 h and by 10 h only
eptide fragments were visible (Fig. 3A); thus this time
oint was chosen for OCX-36 digestion. OCX-36 was  also
igested with thermolysin for up to 4 h, and digestion was
imilarly monitored by SDS-PAGE (Fig. 3B). The peptides
enerated from digestion of OCX-36 with thermolysin were
nly tested for NO analysis in vitro.
dOCX-36 signiﬁcantly reduced LPS-induced TNF-
ecretion from RAW 264.7 cells (p < 0.05) in a dose-
ependent manner, and an almost 50% reduction was
bserved at the highest dose tested (100 g/mL) when
ompared to cells treated with LPS alone (Fig. 4A). Diges-
ion with pepsin also appeared to abrogate the stimulatory
ffect of OCX-36 on RAW 264.7 cells, as dOCX-36 alone did
ot induce TNF- secretion when compared to untreatedmolysin. OCX-36 was incubated with (A) pepsin or (B) thermolysin for
the  times indicated. The position of molecular weight standards (kDa) is
indicated and position of OCX-36 is indicated by the asterisk.
cells. Peptides derived from OCX-36 digested with pepsin
(Fig. 4B) and thermolysin (data not shown), however, did
not show any effect on NO secretion in LPS-stimulated
cells when compared to cells treated with LPS alone. As
with TNF-, dOCX-36 alone did not induce NO production
when compared to untreated cells. Treatment with OCX-
36 digested with pepsin or thermolysin did not affect cell
viability (data not shown).
3.1.3. PCR array analysis
Since both OCX-36 and dOCX-36 exerted differen-
tial effects on TNF- and NO production in RAW 264.7
cells, we  further examined the effects of OCX-36 and
dOCX-36 at the transcriptional level. Cells were incu-
bated for 6 h with medium alone, OCX-36 or dOCX-36
alone, LPS alone, or LPS pre-incubated with dOCX-36
(LPS + dOCX-36), and relative gene expression was  ana-
lyzed by PCR array. Differentially expressed genes are
shown in Table 1. Notably, treatment of cells with dOCX-
36 alone down-regulated expression of Cyb (cytochrome
b-245, beta polypeptide), IL-1f6 (IL-1 family, member 6),
IL-1rn (IL-1 receptor antagonist), Pglyrp1 (peptidoglycan
recognition protein 1) and up-regulated Proc (protein C)
expression when compared to OCX-36. Treatment with
OCX-36 alone down-regulated IL-1 when compared to
LPS, and along with dOCX-36 down-regulated IL-6 expres-
sion. Moreover, when combined with LPS (LPS + dOCX-36),
dOCX up-regulated expression of CCL2 (MCP-1, monocyte
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Table 1
Differentially expressed genes in RAW 264.7 cells treated with OCX-36, dOCX-36, LPS, or LPS+dOCX-36.
Gene symbol Fold changea Functional gene grouping
OCX-36 dOCX-36 LPS LPS+ dOCX-36
Camp − − −2.3 −2.1 Cathelicidin antimicrobial peptide; Defense response to bacteria
CCL2 − − − 2.7 Chemokine involved in inﬂammatory response
CD1d1 2.9 − 3.5 2.4 Innate immune response, detection of bacteria
Colec12 − −2.7 −2.3 −2.0 Antibacterial humoral response
CXCR4 − − − −2.07 Defense response to bacteria, LPS receptor
Cyb −  −2.5 − − Inﬂammatory response, antibacterial humoral response
IFN-1 −  − 7.8 5.4 Innate immune response
IL-10  − −4.55 −4.38 −2.2 Septic shock, apoptosis
IL-1  − − 2.3 2.4 Inﬂammatory response
IL-1  −2.4 − 2.8 − Inﬂammatory response, septic shock
IL-1f6 – −2.3 − − Member of IL-1 family; Inﬂammatory response
IL-1rn – −2.4 − − IL-1 receptor antagonist; Inﬂammatory response, septic shock
IL-6  −2.0 −2.0 − − Inﬂammatory response, septic shock
MyD88 − − − −2.5 NF-B signalling
Pglyrp1 − −2.6 − −2.7 Detection of bacteria, defense response to bacteria
Prg2  − − − −3.6 Defense response to bacteria, inﬂammatory response
Proc − 2.6 − − Protein C; Septic shock
TLR1 3.0 4.3 2.7 − Defense response to bacteria, NF-B signalling
TLR3  2.6 − 2.6 − Defense response to bacteria, NF-B signalling
TLR8  2.5 − − − Detection of pathogens, NF-B signalling
a Cells were treated for 6 h with 1 g/mL OCX-36 or dOCX-36 alone, 100 ng/mL LPS alone, or dOCX-36+LPS, and gene expression was  analyzed by PCR
ene wasarray.  Results are expressed as fold change relative to untreated cells. A g
Numbers in bold and italics indicated down-regulation.
chemotactic protein-1), and down-regulated expression of
CXCR4 (chemokine receptor 4), MyD88 (myeloid differen-
tiation primary response gene 88) and Prg2 (Proteoglycan
2).
3.1.4. Anti-endotoxin effects in vivo
To examine the anti-endotoxin effects in vivo, mice
were injected with a sublethal dose of E. coli O111:B4
LPS and monitored for clinical signs and body weights.
Mice given LPS along with native OCX-36 (LPS + OCX-
36) or pepsin-digested OCX-36 (LPS + dOCX-36) displayed
slightly reduced clinical signs (rufﬂed fur, lethargy) than
mice given LPS alone. While all mice lost weight 24 h after
LPS administration, mice given the high dose (10 mg/kg
BW)  OCX-36 or dOCX-36 lost less weight than positive con-
trol (LPS) mice (p < 0.05) (Fig. 5). Therefore this dose was
chosen for further study. There was no effect of OCX-36 or
dOCX-36 administered alone.
To examine the effects of OCX-36 and dOCX-36 on acute
LPS-induced endotoxemia, levels of pro-inﬂammatory
mediators in the serum, liver and intestine (ileum) were
measured 2 h after i.p. injection of LPS alone, or combined
with OCX-36 or dOCX-36. Administration of LPS + dOCX-
36 reduced serum IL-6 concentrations (p < 0.05) when
compared to LPS-treated mice (Fig. 6A), but did not signiﬁ-
cantly affect serum TNF- (Fig. 6A), or liver IL-6 and TNF-
(Fig. 6B). LPS + OCX-36 had no effect on serum or liver
cytokine concentrations when compared to mice treated
with LPS alone. Levels of pro-inﬂammatory cytokines and
myeloperoxidase (MPO) activity in the ileum were also
measured to examine the effect of OCX-36 and dOCX-36 on
local inﬂammation. IL-6, TNF-, and IL-1 concentrations
were elevated in the ileum of positive control (LPS) mice,
but were signiﬁcantly reduced in mice administered considered differentially expressed when fold change was  at least ± 2.0.
LPS + dOCX-36 (p < 0.05) (Fig. 7A). LPS + OCX-36 did not
signiﬁcantly affect cytokine levels in the ileum when com-
pared to mice treated with LPS alone. The activity of MPO,
an indicator of neutrophil inﬁltration into the intestinal
mucosa, was  signiﬁcantly decreased by treatment with
both LPS + OCX-36 and LPS + dOCX-36 when compared to
positive control (LPS) mice (p < 0.05) (Fig. 7B).
4. Discussion
OCX-36 is a chicken eggshell protein speciﬁcally
expressed in the chicken reproductive and digestive
tracts. Based on similarities in the protein sequence and
exon/intron gene organization with LBP, BPI and PLUNC
family members, it has been proposed that OCX-36 plays a
role in host defense (Gautron et al., 2007; Tian et al., 2010).
LBP/BPI/PLUNC family proteins are capable of recognizing
and neutralizing the effects of LPS (Wurfel et al., 1994;
Wiesner and Vilcinskas, 2010). LBP also binds to other bac-
terial components such as LTA, peptidoglycan breakdown
products and lipopeptides, and has been shown to mod-
ulate the effects of LTA in macrophages and monocytes
(Schumann, 2011). We recently demonstrated that OCX-36
has antimicrobial activity against S. aureus and afﬁnity
for bacterial endotoxin (E. coli LPS) and non-endotoxin
pyrogen (S. aureus LTA) (Cordeiro et al., 2013). OCX-36 can
be readily extracted directly from eggshell membranes.
This is a clear difference in comparison to the other innate
immune proteins such as LBP, BPI and PLUNC proteins since
most studies examining these proteins utilize recombinant
proteins (Amura et al., 1998; Lamping et al., 1998; Chen
et al., 2007). In the current study, we generated peptides
by OCX-36 digestion and compared the effect of full-length
OCX-36 and OCX-36-derived peptides on LPS-induced
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Fig. 4. Effect of OCX-36-derived peptides (dOCX-36) on TNF- and NO secretion in LPS-stimulated RAW 264.7 cells. (A) Cells were treated with 0, 0.1, 1,
10  or 100 g/mL dOCX-36 in the presence or absence of 100 ng/mL E. coli LPS for 6 h. TNF- concentration was measured by ELISA, and is presented as
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NF- and NO production in RAW 264.7 macrophage cells
n vitro, and in vivo using a mouse model of endotoxemia.
Macrophages are phagocytic cells that attack infectious
athogens through the secretion of immune modulating
ediators (Rosenberger and Finlay, 2003). Activation of
acrophages in vitro by LPS induces production of pro-
nﬂammatory mediators, including TNF-, IL-6, IL-1 and
O (Zhu et al., 2013). Our in vitro experiments demon-
trated that OCX-36 displayed a moderate inhibitory effect
n LPS-induced TNF- secretion and a stimulatory activ-
ty on NO production in RAW 264.7 cells. Previous studies
ave shown that human recombinant BPI and LBP inhib-
ted the ability of LPS to stimulate TNF-, but only BPI was
ble to suppress the production of TNF- and NO on mouse
acrophages (Amura et al., 1997, 1998). This is in line with
ur ﬁndings that OCX-36 exerted distinct effects on LPS-
nduced TNF- and NO secretion from RAW 264.7 cells.
he authors were unable to detect differences in TNF-
r inducible nitric oxide synthase (iNOS) gene expression,
PS-induced phosphorylation or activation of the NF-B
ranscription factor by either LBP or BPI, and suggested
ownstream regulation of LPS-mediated signaling events
r the presence of two independent membrane bindingre treated with 0 or 60 g/mL of pepsin-digested OCX-36 in the presence
sing Griess reagent. Data represent means ± SEM, n = 3. Values without a
sites for LPS used by LBP and BPI protein to activate LPS
stimulated murine macrophages (Amura et al., 1997, 1998).
We also observed that at high doses, OCX-36 alone could
signiﬁcantly enhance the production of TNF- and NO by
mouse macrophages, indicating that OCX-36 can also exert
immunostimulatory effects.
The inhibitory effect of LBP on TNF- secretion in
murine macrophages stimulated with LPS was  previously
reported to occur in both the presence and absence of
murine serum (Lamping et al., 1998). Here, OCX-36 like-
wise reduced TNF- secretion by LPS-activated RAW 264.7
cells in both the absence and presence of 10% FBS. FBS is a
source of LBP and a percentage of bioactive LBP in FBS is able
to promote cell activation with murine and human TLRs
(Meszaros et al., 1995). The reduction in TNF- secretion
from LPS-stimulated RAW 26.4 cells treated with OCX-36
in the absence of serum suggested that OCX-36 may  com-
pete with LBP for LPS and lead to an inhibition of TNF-
secretion. The observation that OCX-36 did not reduce TNF-
 secretion when added to the cells at different time points
independent of LPS and without pre-incubation (data not
shown) further supports the role of the interaction of OCX-
36 with LPS in anti-inﬂammatory activity.
8 J. Kovacs-Nolan et al. / Veterinary Immunology a
Fig. 5. Effect of OCX-36 and dOCX-36 on LPS-induced weight loss in mice.
Mice were injected i.p. with 25 g LPS combined with 2 or 10 mg/kg
BW OCX-36 or dOCX-36 in sterile saline. Positive control (LPS) mice
received E. coli LPS alone, and negative control (Saline) mice received
saline only. Mice were weighed before and 24 h after LPS injection.
n  = 5–10 mice/group. Each data point represents an individual animal, and
horizontal lines indicate mean values. *p < 0.05.
We  next examined the effect of OCX-36-derived
peptides on TNF- and NO secretion in RAW 264.7
cells. Synthetic peptides derived from LBP and BPI have
been shown to prevent LPS-induced TNF- secretion
by macrophages, and have been suggested as a poten-
tial adjunctive therapy to conventional sepsis treatments
(Battafarano et al., 1995; Dankesreiter et al., 2000). More
recently, a synthetic peptide (GL13NH2) from parotid
secretory protein, a PLUNC member protein, was  simi-
larly found to reduce the LPS-stimulated release of TNF-
from RAW 264.7 cells (Abdolhosseini et al., 2012). Here,
OCX-36 was digested with pepsin, to mimic  digestion in
the gastrointestinal tract. Several studies have shown that
peptides derived from chicken egg proteins digested with
pepsin exhibit broad antimicrobial activity spectrum, anti-
oxidant activity and reduced allergenicity (Kovacs-Nolan
et al., 2000; Mine et al., 2004). OCX-36-derived peptides
showed a different effect on TNF- and NO secretion
by RAW 264.7 cells when compared to full-length OCX-
36. Pepsin-digested OCX-36 had enhanced anti-endotoxin
effects and reduced LPS-induced TNF- secretion by almost
50%. On the other hand, OCX-36 digested with pepsin or
thermolysin did not show any inhibitory effect on NO
release by LPS-stimulated murine macrophages. Moreover,
in contrast to full-length OCX-36, OCX-36-derived pep-
tides alone had no immunostimulatory activity and did not
induce NO or TNF- production.
The differential effects of OCX-36 and OCX-36-derived
peptides on NO and TNF- production in RAW 264.7
macrophages, both alone and in the presence of LPS, were
further examined by the expression proﬁling of several
genes involved in innate immunity and inﬂammation.
OCX-36 alone down-regulated the expression of pro-
inﬂammatory cytokines IL-1 and IL-6, but up-regulatednd Immunopathology 160 (2014) 1–11
molecules involved in bacterial antigen recognition
and presentation, such as CD1d and TLR8, which can
lead to downstream activation of NF-B (Joyce, 2001;
Cervantes et al., 2012), further supporting its role in
activation of innate immunity. Likewise, dOCX-36 alone
down-regulated the expression of molecules involved
in inﬂammation, including the oxidative stress-related
molecule cytochrome b-245, IL-1F6, a member of the IL-1
cytokine family that activates NF-B, and IL-1 receptor ago-
nist, which regulates IL-1-mediated inﬂammation (Towne
et al., 2004). In addition, dOCX-36 up-regulated protein
C, which has been shown to exert anti-inﬂammatory
effects in acute inﬂammation and sepsis (Frommhold et al.,
2011). In the presence of LPS, dOCX-36 up-regulated CCL2
(MCP-1), an important mediator of monocyte/macrophage
recruitment, which has been shown to induce NO produc-
tion in mouse macrophages in vitro (Biswas et al., 2001).
dOCX-36 also down-regulated the expression of MyD88
and CXCR4 in LPS-activated RAW 264.7 cells. MyD88  is
a TLR adapter protein important for TLR4 cell signal-
ing pathways and is involved in systemic inﬂammation
and mortality during sepsis. The CXCR4 receptor plays
important functions, which, along with CD14, TLR4 and
MD-2, may  also play a role in LPS binding and signal-
ing (Triantaﬁlou and Triantaﬁlou, 2002; Feng et al., 2011).
Surprisingly, expression of the anti-inﬂammatory cytokine
IL-10 was down-regulated in cells treated with dOCX-36,
LPS, and to a lesser extent, LPS + dOCX-36. Decreased IL-
10 production in LPS-stimulated macrophages has been
described in response to anti-inﬂammatory treatments
(Babcock et al., 2002), and Amura et al. (1998) found that
BPI and LBP did not alter IL-10 expression in LPS-stimulated
mouse macrophages despite a signiﬁcant reduction in LPS-
induced TNF- secretion. While these results suggest that
IL-10 may  not be involved in the anti-endotoxin effects of
dOCX-36 observed here, further gene expression analysis
at different time points may  be required to elucidate the
role of IL-10 in response to OCX-36/dOCX-36 treatment.
The anti-endotoxin activity of pepsin-digested OCX-36
(dOCX-36) in vitro motivated us to use a mouse model of
endotoxemia to examine the effects of dOCX-36 on the
levels of pro-inﬂammatory cytokines in various organs.
Our data showed that dOCX-36 signiﬁcantly reduced IL-6,
but not TNF- levels in the serum of mice following i.p.
treatment with LPS. While TNF- is important in inﬂam-
mation, IL-6 plays a key role in the acute phase response
during sepsis and endotoxemia, and in fact circulating IL-6
levels have been found to be more closely correlated with
disease severity and mortality than other inﬂammatory
cytokines in patients with septic shock (Damas et al.,
1992; Liaw et al., 1997). In addition, dOCX-36 was able to
decrease the levels of IL-6, TNF- and IL-1, as well as MPO
activity, in the ileum of mice administered LPS + dOCX-36.
Both OCX-36 and dOCX-36 were able to decrease local
LPS-induced MPO  activity, suggesting the potential to
reduce the recruitment of neutrophils in the ileum of
septic mice. TNF-, IL-6 and IL-1 are pro-inﬂammatory
cytokines that play important roles in the intestinal
mucosa during endotoxemia. Increased levels of these
cytokines might affect the intestine as well as the function
and integrity of remote organs and tissues (Meyer et al.,
J. Kovacs-Nolan et al. / Veterinary Immunology and Immunopathology 160 (2014) 1–11 9
Fig. 6. Effect of OCX-36 and dOCX-36 on TNF- and IL-6 concentrations in the (A) serum and (B) liver of LPS-treated mice. Mice were injected i.p. with 25 g
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ollected 2 h after injection and cytokine levels in serum and liver homoge
p  < 0.05 compared to LPS.
995; Pritts et al., 2002). The intestinal anti-inﬂammatory
ctivity of OCX-36 peptides suggested that dOCX-36 can
odulate the intestinal mucosal immune response during
ndotoxemia. Both LBP and BPI are present in the intestinal
pithelium, and overexpression of BPI was shown to atten-
ate bacteria-induced inﬂammation in intestinal epithelial
ells, suggesting the potential for oral administration of
CX-36-derived peptides (Vreugdenhil et al., 2000; Canny
t al., 2006). There are a number of reports describing
he anti-endotoxin activity of BPI and recombinant BPI
eptides in vivo (Levy, 2002). Recombinant chimeric pro-
ein BPI23-Fc1 displayed anti-endotoxin and bactericidal
ctivity and increased the survival rate of mice with sepsis
aused by Gram-negative infection (Chen et al., 2007),
nd Jiang et al. (2004) found that a synthetic BPI peptide
t a dose of 10 mg/kg could protect animals from lethal
ndotoxemia and reduce production of TNF- and IL-6.
hile recombinant LPB at high doses has also been shown
o protect mice against septic shock in vivo, it is highlytive control (LPS) mice received LPS alone. Blood and liver samples were
easured by ELISA. Values shown are means ± SEM for n = 6–8 mice/group.
dependent on LBP concentration, as lower doses have been
found to pontentiate cell responses to LPS (Lamping et al.,
1998), and as such LBP-derived peptides that can prevent
LPS-induced TNF- secretion in vitro and in vivo, indepen-
dent of LBP concentration, have also been reported (Aran˜a
et al., 2003). Likewise, the OCX-36-derived peptides tested
here lacked the immunostimulatory activity of native
OCX-36, and may  therefore be beneﬁcial for the treatment
of sepsis and inﬂammation.
Overall, in vitro studies revealed that puriﬁed OCX-36
reduces LPS-induced secretion of TNF- from macrophages
and that OCX-36-derived peptides possess potent anti-
endotoxin properties. The neutralizing activity of digested
OCX-36 was  conﬁrmed by its capability to down-regulate
the expression of genes involved in LPS signaling and
inﬂammatory responses. OCX-36 might promote LPS acti-
vation in RAW 264.7 cells to augment some macrophage
functions such as NO and TNF- production. This sug-
gests that OCX-36 is also a potential candidate as an
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Fig. 7. (A) Cytokine and (B) MPO  concentrations in the ileum of LPS-treated mice. Mice were injected i.p. with 25 g E. coli LPS combined with 10 mg/kg BW
PS alone
ay, respOCX-36 or dOCX-36 in sterile saline. Positive control (LPS) mice received L
MPO  activity in ileum homogenates were measured by ELISA and MPO  ass
compared to LPS.
immunostimulator of NO and TNF-, which are impor-
tant cytotoxic mediators contributing to the bactericidal
activity of macrophages. Similar to our in vitro data, OCX-
36-derived peptides were found to have an inhibitory effect
on the production of LPS-induced pro-inﬂammatory medi-
ators associated with endotoxemia in vivo. A future study
to isolate and identify the effective anti-inﬂammatory
OCX-36 peptides may  lead to development of a novel
endotoxin-neutralizing therapeutic agent or to deliv-
ery of OCX-36 as a nutraceutical by oral ingestion is
conceivable.
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